2011
DOI: 10.1016/j.neuropharm.2010.06.002
|View full text |Cite
|
Sign up to set email alerts
|

Binding site and ligand flexibility revealed by high resolution crystal structures of GluK1 competitive antagonists

Abstract: The availability of crystal structures for the ligand binding domains of ionotropic glutamate receptors, combined with their key role in synaptic function in the normal and diseased brain, offers a unique selection of targets for pharmaceutical research compared to other drug targets for which the atomic structure of the ligand binding sites is not known. Currently only a few antagonist structures have been solved, and these reveal ligand specific conformational changes that hinder rational drug design. Here w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
30
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 24 publications
(34 citation statements)
references
References 52 publications
(82 reference statements)
4
30
0
Order By: Relevance
“…For the DKAiR1D AP5 complex, after superposition using domain 1 coordinates, rotations of 30° and 23° for the A and B subunits were required to superimpose domain 2 on the closed cleft DKaiR1D glutamate complex (Figure 5D and Figures S3D and E). The 30° opening observed for the B subunit of the AP5 complex (Figure 5D) is similar to the opening observed for several vertebrate GluK1 antagonist structures (Alushin et al, 2011; Mayer et al, 2006), and much larger than for vertebrate GluN2A NMDA receptors (Figure 5D) for which D-AP5 produces only 15° opening (Jespersen et al, 2014). …”
Section: Resultssupporting
confidence: 79%
“…For the DKAiR1D AP5 complex, after superposition using domain 1 coordinates, rotations of 30° and 23° for the A and B subunits were required to superimpose domain 2 on the closed cleft DKaiR1D glutamate complex (Figure 5D and Figures S3D and E). The 30° opening observed for the B subunit of the AP5 complex (Figure 5D) is similar to the opening observed for several vertebrate GluK1 antagonist structures (Alushin et al, 2011; Mayer et al, 2006), and much larger than for vertebrate GluN2A NMDA receptors (Figure 5D) for which D-AP5 produces only 15° opening (Jespersen et al, 2014). …”
Section: Resultssupporting
confidence: 79%
“…5). However, although the overall displacement of the LBD in each subunit is clearly visible, we cannot resolve the change in cleft closure that occurs in response to binding of agonist compared with the antagonist bound state (29,31); likewise, the orientation of the ligand binding site in individual LBD monomers cannot be determined with certainty at the present resolution. Nevertheless, the fits provide an impression of dramatic changes in the LBD layer that occur when binding of glutamate triggers desensitization and show how the overall conformational change between the two states might be considered to resemble the winding and unwinding of the bundle of four monomers that constitute the tetrameric receptor assembly (Movie S2).…”
Section: Stabilization Of Gluk2mentioning
confidence: 78%
“…With the goal of establishing a highly populated desensitized state suitable for structural analysis we used the agonist 2S,4R-4-methylglutamate, which binds to GluK2 with 100-fold higher affinity than glutamate (28). Likewise, to stabilize an antagonist-bound resting state we introduced four-point mutations, A487T, A658S, N690S, and F704L, based on the GluK1 LBD crystal structure (29) to create a binding site for the GluK1 selective competitive antagonist LY466195, K d 38 nM. Using tryptophan fluorescence size-exclusion chromatography (30), we established that GluK2 preparations at concentrations of 1-2 mg/ mL are monodisperse in both the resting and desensitized states when stored at 4°C in a buffer containing 2 mM n-dodecyl-β-Dmaltopyranoside (DDM) and 0.3 mM cholesterol hemisuccinate ( Fig.…”
Section: Stabilization Of Gluk2mentioning
confidence: 99%
“…One X-ray structure of a full length iGluR (AMPA subtype) is available today (Sobolevsky et al, 2009); however, most of the structural studies of iGluRs were made on isolated soluble domains. Within the kainate receptor subfamily numerous structures of the GluK1 LBD and several structures of the GluK2 LBD have been solved in complex with agonists: among others glutamate (Mayer, 2005), kainate (Plested et al, 2008), domoic acid (Hald et al, 2007), dysiherbaine (Frydenvang et al, 2009) and antagonists, such as ATPO (Hald et al, 2007) and compounds of UBP series (Alushin et al, 2010;Mayer et al, 2006). The structural information has provided key insights into biostructural mechanisms underlying receptor activation (Hald et al, 2007;Mayer, 2005) and continuously aids the design of new potential iGluR ligands (Larsen and Bunch, 2010;.…”
Section: Introductionmentioning
confidence: 99%